Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare has received FDA approval for its hepatitis A treatment, Kogenate FS, to be stored at room temperature for up to three months. The new storage guidelines for the treatment will provide users with greater flexibility and simplify storage options.
Subscribe to our email newsletter
The FDA approved the storage labeling change based on data from testing to assure the labeled potency remains within specified limits through the expiration date of the product. The room temperature storage option is expected to be a significant convenience for Kogenate FS users.
Starting in November 2005, each package of Kogenate FS will include a special notification with details on the new labeling. While the new room temperature storage option may be used, Bayer recommends refrigerating Kogenate FS whenever possible.
“We are pleased with the approval and the opportunity to provide our customers with this convenience,” said Terry Tenbrunsel, vice president of sales and marketing at Bayer BP.